Eurocine Vaccines´ nasal influenza vaccine candidate Immunose™ FLU showed good safety in clinical study

Eurocine Vaccines today announced that Immunose™ FLU, a quadrivalent influenza vaccine candidate showed good safety in a clinical phase I/II study. Immunose™ FLU is a novel nose drop formulation based on the company´s technology Endocine™ and inactivated split influenza antigens. Immunological results from the study are expected in third quarter 2017.

The trial was primarily designed to study the safety and tolerability of Immunose™ FLU in healthy adults, 18-39 years of age. The clinical phase of the study was conducted between late October 2016 and early January 2017 at two clinics in Sweden. A total of 162 subjects were dosed in the study and 159 subjects completed all visits.

Immunose™ FLU formulations with different concentrations of Endocine™ were studied, as well as a placebo and nasal and injected comparator products. The reported adverse events were mostly mild or moderate and the most common adverse events in the Immunose™ FLU groups were transient irritation and pain in the throat.  

No subjects withdrew due to adverse events and there was a high percentage (98 %) of subjects who completed the clinical phase of the study. One serious adverse event (bacterial infection in the skin) was reported, and was deemed not related to the study product.

“We are happy to once again confirm the good safety of our nasal technology platform,” said Dr. Anna-Karin Maltais, Chief Scientific Officer and continued: “Now we are looking forward to the results of the extensive immunological analyses. The evaluation of the immune responses induced by Immunose™ FLU is expected to be reported in third quarter 2017”.

Dr. Hans Arwidsson, Chief Executive Officer, added “The positive safety results obtained in adults is an important milestone, which strengthens us on our path towards a better influenza vaccine for children.”

Eurocine Vaccines is using its clinically validated technology Endocine™ to develop a patent protected nasal influenza vaccine for children. Within the market for influenza vaccines, children is the fastest growing segment. This is due to the recommendation by the WHO to vaccinate children against influenza. The company´s main project, the nasal quadrivalent influenza vaccine candidate Immunose™ FLU, is in clinical phase I/II development during the influenza season 2016/2017 and a report on the study is expected in third quarter 2017.

The company plans to license the product to partners for further development and commercialization.

Eurocine Vaccines, EUCI, is traded at Aktietorget, XSAT.

För en utförligare beskrivning av Eurocine Vaccines verksamhet, se Bolagets årsredovisning för räkenskapsåret 2015/2016 och www.eurocine-vaccines.com.

Eurocine Vaccines är listat på AktieTorget.